Latest news with #TelixPharmaceuticals
AU Financial Review
3 days ago
- Business
- AU Financial Review
Waiting to get rich from biotech? Don't hold your breath
Investing in biotechs and other healthcare start-ups has long been notoriously high risk, high reward. The global Australian success stories such as CSL and Cochlear and relative newcomers, including Telix Pharmaceuticals and Neuren Pharmaceuticals, are examples of the upside for investors prepared to take a punt on a company even when it is years away from generating revenue.
Yahoo
11-07-2025
- Business
- Yahoo
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability. Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix's enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)'s stock has a consensus price objective of $22.92. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
11-07-2025
- Business
- Business Insider
Bell Potter Remains a Buy on Telix Pharmaceuticals (TLPPF)
Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company's shares closed today at $16.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Hester is a 3-star analyst with an average return of 5.2% and a 51.58% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Clarity Pharmaceuticals Ltd., and Paragon Care Limited. Currently, the analyst consensus on Telix Pharmaceuticals is a Strong Buy with an average price target of $22.08.
Yahoo
10-07-2025
- Business
- Yahoo
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability. Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix's enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)'s stock has a consensus price objective of $22.92. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Sky News AU
03-07-2025
- Business
- Sky News AU
ASX 200 zig-zags on Thursday as investors await over-50s accomodation company GemLife to go public in 2025's biggest IPO
The ASX 200 has soared before undoing its gains on Thursday as investors await over-50s accommodation company GemLife going public at midday in what is expected to be the biggest initial public offering (IPO) of the year. The index has shed 0.2 per cent in the first 40 minutes of trading with Boss Energy sinking 4.1 per cent, Telix Pharmaceuticals falling 3.7 per cent and Vault Mineral dropping 3.6 cent. Strong performers on Thursday include Pilbara Minerals (up 10.6 per cent), Whitehaven Coal (up 8.2 per cent) and Helia Group (up 7.9 per cent) which has bounced back after sinking more than 20 per cent on Wednesday after informing shareholders ING was seeking a new mortgage insurance partner. Investors will watch over-50s accommodation company GemLife's initial public offering. The business has tapped investors for $750m, exceeding Virgin Australia's $685m it raised from its recent IPO, with shares going for $4.16. It primarily operates homes across Australia's east coast and is poised to grow as the nation's population ages. Qantas shares have bounced back 1.1 per cent after it suffered a share price plunge from its cyber attack that put six million of its customers' records at risk. Domino's has jumped 4.7 per cent after sinking 15 per cent on Wednesday following the abrupt resignation of its chief executive officer. Wall Street generally grew on Wednesday with the tech heavy Nasdaq rising 0.9 per cent, driven by a boost in Tesla after it revealed better than expected sales along with Nvidia adding 2.6 per cent and Apple rising 2.2 per cent. The S&P 500 grew half a per cent while the Dow Jones finished flat. London's FTSE 250 Index sank 1.3 per cent on Wednesday, Germany's DAX rose 0.5 per cent and the STOXX Europe 600 Index added 0.2 per cent. New Zealand's NZX 50 Index is down half a per cent since trading began on Thursday while Japan's Nikkei 225 has slumped 0.2 per cent.
